Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex already generates billions in revenue -- but there may be more to come.

Missed Out On Axsome Therapeutics? My Best Biotech Stock to Buy and Hold

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the advancement of its investigational program targeting alpha-1 antitrypsin deficiency (AATD), a rare, genetic disease characterized by a protein folding defect that can lead to liver and lung disease. Vertex announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) Application for VX-634 enabling the company to initiate a first-in-human clinical trial for

Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency

Cheniere Energy

Wolfspeed

With plans to build the world's largest silicon carbide plant and big EPS estimates ahead, Wolfspeed looks to charge up a fresh breakout. The post Silicon Carbide Leader Drives EVs, 5G — And Strong Sales appeared first on Investor's Business Daily.

Silicon Carbide Leader Drives EVs, 5G — And Strong Sales

Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.

Here's Why You Should Invest in Vertex (VRTX) Stock Now

AbbVie

Axsome Therapeutics

Biogen

Exelixis

Eli Lilly

Regeneron Pharmaceuticals

Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure.

These 7 Biotech Stocks Are Set to Boom in 2023

Incyte

One is doing much better than the other year to date, but they both have solid prospects ahead.

2 Cathie Wood Stocks That Are Beating the Market This Year

Vertex Pharmaceuticals is approaching a buy point as this biotech stock expands into other markets, gains institutional investors. The post This Biotech Stock Nears Buy Point As It Expands Into Other Markets appeared first on Investor's Business Daily.

This Biotech Stock Nears Buy Point As It Expands Into Other Markets

Bristol-Myers

These high-flying stocks are defying the bear market.

3 Stocks Savvy Investors Are Buying Hand Over Fist

The company has a potential blockbuster drug that was granted rolling review status by the FDA.

Why Vertex Pharmaceuticals' Shares Rose 2.8% in September

Intuitive Surgical

3 Healthcare Stocks That Could Make You Richer

CRISPR Therapeutics

The two companies are collaborators, but they aren't equally likely to be a better purchase than Amazon.

1 Growth Stock That'll Beat Amazon and 1 That Probably Won't (for Now)

Vertex's cystic fibrosis franchise is the main source of value at present. Q2 revenue was up 22% from the year-earlier.

Vertex Pharmaceuticals: A Buy For Growth Potential

Spiros Segalas (Trades, Portfolio), manager of the Harbor Capital Appreciation Fund, disclosed his 13F portfolio for the third quarter of 2022 last week.

Spiros Segalas Snatches Up Vertex Pharmaceuticals, Sells Snap

Cardinal Health

DoubleVerify Holdings

Neurocrine Biosciences

Paylocity Hlds

Shockwave Medical

As the market indexes work through a downturn, Vertex is among nine stocks to watch showing relative strength. The post Vertex Among 9 Stocks To Watch In Struggling Market appeared first on Investor's Business Daily.

Vertex Among 9 Stocks To Watch In Struggling Market

Catalyst Pharmaceuticals

As the market indexes work through a downturn, Vertex is among eight stocks to watch showing relative strength. The post Vertex Among 8 Stocks To Watch In Struggling Market appeared first on Investor's Business Daily.

Vertex Among 8 Stocks To Watch In Struggling Market

Pfizer

Two of these three stocks are already soaring this year.

3 Growth Stocks Poised to Skyrocket

Procter & Gamble

The stocks can lend growth and peace of mind as you add to your portfolio.

Got $1,000? 2 Safe Stocks to Buy This Month

Vertex Pharmaceuticals stock (NASDAQ: VRTX) has seen a 33% rise this year, significantly outperforming the broader S&P500 index, down 23%.

What's Driving Vertex Pharmaceuticals Stock Higher?

Dollar General

UnitedHealth Group

You can sleep peacefully owning these stocks.

3 Stocks to Buy if You're Afraid to Buy Stocks

As biotech leaders Vertex and Crispr shoot for a gene-editing first, VRTX stock takes aim at a new breakout. The post Vertex Nears Buy, Joins Crispr To Advance A Gene-Editing First appeared first on Investor's Business Daily.

Vertex Nears Buy, Joins Crispr To Advance A Gene-Editing First

Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.

Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy

Costco

These companies are successful today, and they're on track to be successful tomorrow too.

The 2 Best Stocks to Invest $5,000 in Right Now

The biotech's exa-cel will be the subject of a rolling review by the FDA.

Why Vertex Pharmaceuticals Stock Triumphed On Tuesday

CRISPR Therapeutics Inc. CRSP, +7.21% and Vertex Pharmaceuticals Inc. VRTX, +3.04% said Tuesday that the Food and Drug Administration granted a rolling review to the exagamglogene autotemcel, the therapy the companies are developing to treat sickle cell disease and transfusion-dependent beta thalassemia. CRISPR's stock was up 3.1% in premarket trading on Tuesday, while Vertex shares gained 1.1%.

CRISPR, Vertex say FDA granted rolling review to experimental CRISPR therapy

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that Vertex has concluded discussions with the U.S. Food and Drug Administration (FDA), and the FDA granted exagamglogene autotemcel (exa-cel) a rolling review for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Vertex will submit its biologics licensing application (BLA) for exa-cel for rolli

News for Vertex Pharmaceuticals Stock (VRTX)